#Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Announces Partial Repurchase of 1% Convertible Senior Notes Due 2027

Alnylam Pharmaceuticals Yesterday, December 11, 2025, Alnylam Pharmaceuticals, Inc. ( ALNY ) announced that it has entered into separate, privately negotiated repurchase agreements with certain holder...

P

Prohost Biotech

Dec 12, 2025

Alnylam Pharmaceuticals Announces Proposed Offering of $500 Million Convertible Senior Notes. The Stock's Price is Soaring.

Alnylam Pharmaceuticals Press Release Alnylam Pharmaceuticals, Inc. ( ALNY ) , the leading RNAi therapeutics company, announced today that it has commenced a private offering of $500 million aggregate...

P

Prohost Biotech

Sep 9, 2025

Alnylam's Presentation In Early September

Alnylam Pharmaceuticals Presentations In early September 2025, Alnylam Pharmaceuticals ( ALNY ) will present two investor conferences. The presentations will be webcast, providing company updates for...

P

Prohost Biotech

Aug 28, 2025

How Alnylam Pharmaceuticals Made Our Day Today and More

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress The Financial Results and More Today, July 31, 2025, Alnylam Pharmaceuticals ( ALNY ) - the...

P

Prohost Biotech

Jul 31, 2025

Today About: Alnylam Pharmaceuticals, Bristol-Myers Squibb and Intellia Therapeutics

Friday, August 18, 2025 Solid Earning, revenue growth, President Trump signing crypto bills, and Crispr Therapeutics stocks finally surge with the stocks following are happening today in spite of ext...

P

Prohost Biotech

Jul 18, 2025

Alnylam Pharmaceuticals Receives EC Approval for AMVUTTRA® for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam Pharmaceutical's News Today is Great Before we get to the press release from Alnylam Pharmaceuticals we remind that tomorrow, Tuesday, June 10, 2025, Akero Therapeutics’ management will prese...

P

Prohost Biotech

Jun 9, 2025

Alnylam Pharmaceuticals Reported Its Q1 2025 Financial Results and Highlights Recent Period Progress

Alnylam Pharmaceuticals Synopsis Today, May 1, 2025 - Alnylam Pharmaceuticals ( ALNY ), the leading RNAi therapeutics company reported its consolidated financial results for the first quarter ended M...

P

Prohost Biotech

May 1, 2025

The U.S. FDA Approved Alnylam Pharmaceuticals' Product Qfitlia to Treat Hemophilia A or B With or Without Inhibitors

Stock Market Plummet and Alnylam Pharmaceuticals Good News Today, the stock market is plummeting. In fact, most stocks have been falling since early morning. The reason has nothing to do with the comp...

P

Prohost Biotech

Mar 31, 2025

FDA Approved Alnylam Pharmaceuticals sNDA for AMVUTTRA® - A Treatment for Cardiomyopathy of Wild-Type or Hereditary Transthyretin-Mediated Amyloidosis in Adults to Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations and Urgent Heart Failure Visits

Alnylam Pharmaceuticals in the NEWS March 20, 2025, Alnylam Pharmaceuticals ( ALNY ) - the leading RNAi therapeutics company, today announced that the U.S. FDA has approved the supplemental New Drug...

P

Prohost Biotech

Mar 21, 2025

Altimmune, AstraZeneca and Alnylam Pharmaceuticals

Altimmune Altimmune ( ALT ) stock soared last Friday after speculation of a takeover by three large companies. The speculation died today. Nevertheless, other news about this firm could be important...

P

Prohost Biotech

Mar 17, 2025

Alnylam Pharmaceuticals Press Release Highlights Significant Pipeline Progress and Platform Innovation at R&D Day

– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis, cardiovascular disease, and Neuroscience, each representing a blockbuster opportunity – – Announces T...

P

Prohost Biotech

Feb 25, 2025

Q & A About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Questions & Answers Q: Why has Alnylam Pharmaceuticals’ stock plummeted recently? A: We do not forget that Alnylam Pharmaceuticals ( ALNY ) is the leading RNAi Therapeutics. Ke...

P

Prohost Biotech

Feb 19, 2025

Merck Discontinues Two Late-Stage Keytruda Trials and Other Important Information

Merck Updates Merck ( MRK ) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, stating that it discontinued Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA in combination with stereota...

P

Prohost Biotech

Aug 29, 2024

Prohost Letter #461 ~ Preventing HIV Infection and Treating Primary Biliary Cholangitis

Prohost Letter #461 Preventing HIV Infection and Treating Primary Biliary Cholangitis Gilead Sciences Gilead Sciences’ ( GILD ) stock price has been paralyzed for more than three consecutive years. T...

P

Prohost Biotech

Aug 21, 2024

Alnylam Pharmaceuticals: Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran

Alnylam Pharamceuticals Announcement June 24, 2024, Alnylam Pharmaceuticals ( ALNY ) announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeut...

P

Prohost Biotech

Jun 24, 2024

Treating Untreatable Disease - NASH

Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis The efforts spent on treating Non Alcoholic Steatohepatitis (NASH) have reached a promising stage where clinical...

P

Prohost Biotech

Oct 13, 2022

Alnylam Pharmaceuticals: Positive New Results of Lumasiran in Advanced Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals Alnylam Pharmaceuticals ( ALNY ) led the translation of RNA interference ( RNAi ) into a new class of innovative therapeutics, transforming the lives of people afflicted with r...

P

Prohost Biotech

May 25, 2022

Prohost Letter #444

Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio stocks’ targets for the year failed to materialize; nobody not even the authorities were capable of predict...

P

Prohost Biotech

Mar 8, 2021

The US FDA Approved Alnylam's OXLUMO™ Injection to Lower Urinary Oxalate Levels in Pediatric and Adult Patients with PH1

Alnylam Announces FDA Approval o f OXLUMO™ Injection for PH1 Alnylam ( ALNY ) announced that the US FDA has approved its subcutaneous OXLUMO™ (lumasiran) injection, the first-ever therapy available fo...

P

Prohost Biotech

Nov 24, 2020

Fighting COVID-19. See Also: Stocks Gains Following the Market's Rebounding

Treating and Preventing COVID-19 Treating COVID-19, Gilead Sciences With regard to treating patients with COVID-19 we believe the most expected product to be used during this virus' outbreak will be G...

P

Prohost Biotech

Mar 5, 2020

1m

2